Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Net Cash Flow (2021 - 2025)

Aligos Therapeutics' Net Cash Flow history spans 5 years, with the latest figure at -$23.6 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 1519.15% year-over-year to -$23.6 million; the TTM value through Dec 2025 reached -$18.7 million, up 81.05%, while the annual FY2025 figure was -$18.7 million, 81.05% up from the prior year.
  • Net Cash Flow reached -$23.6 million in Q4 2025 per ALGS's latest filing, down from $23.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $65.3 million in Q4 2023 to a low of -$111.4 million in Q1 2024.
  • Average Net Cash Flow over 5 years is -$10.1 million, with a median of -$7.4 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: surged 1390.45% in 2023, then crashed 4551.65% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$53.4 million in 2021, then soared by 90.53% to -$5.1 million in 2022, then soared by 1390.45% to $65.3 million in 2023, then tumbled by 97.45% to $1.7 million in 2024, then tumbled by 1519.15% to -$23.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Net Cash Flow are -$23.6 million (Q4 2025), $23.3 million (Q3 2025), and -$55.1 million (Q2 2025).